Zacks4d agoneutral
Doximity (DOCS) Lags Q4 Earnings EstimatesDoximity (DOCS) delivered earnings and revenue surprises of -7.14% and +1.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Actualités
Uniquement les titres à fort signal — événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
55last 24h
1680last 7d
312🟢 bullish (7d)
171🔴 bearish (7d)
136publishers
Zacks6d agobearish
Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Misses Revenue EstimatesHims & Hers Health (HIMS) delivered earnings and revenue surprises of -519.58% and -1.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks9d agoneutral
Can Platform Expansion Support Hims & Hers Stock Before Q1 Earnings?HIMS first-quarter 2026 results are likely to benefit from Labs and branded weight loss medications even as higher costs and GLP-1 scrutiny linger.
Zacks10d agobullish
Enovis (ENOV) Q1 Earnings and Revenues Beat EstimatesEnovis (ENOV) delivered earnings and revenue surprises of +8.54% and +3.68%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?